ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2801

Predictors of Incident Episodes of Proteinuria Among Patients with Systemic Lupus Erythematosus

Laurence S Magder1, Ali Duarte-Garcia2, Erik Barr3 and Michelle Petri4, 1Epidemiology and Public Health, Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD, 2Medicine, Tufts Medical Center, Boston, MA, 3Epidemiology, University of Maryland, Baltimore, MD, 4Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Clinical, Nephritis, proteinuria, risk and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Lupus nephritis remains one of the most devastating SLE complications, occurring in over 50% of the patients.  It is important to identify clinical conditions that precede nephritis for the purposes of patient care and to identify preventive strategies.  Most previous studies of predictors of incident nephritis in SLE are cross-sectional or do not incorporate time-varying predictors. We leveraged a large clinical cohort which evaluated patients quarterly to identify fixed and time-varying predictors of lupus nephritis.

Methods: Since 2006, the urine protein/creatinine ratio was measured quarterly in patients in our SLE cohort.  This analysis was based on cohort follow-up after 2006 in patients who did not have a history of diabetes and who did not have a prior episode of sustained elevated proteinuria, nor a  history of nephritis, renal insufficiency, or failure.  Among these patients, we defined an incident case of proteinuria as two or more measures of urine protein/creatinine (or 24-hour protein measure) greater than 0.5 in two visits separated by more than 30 days and less than 180 days, among patients with no prior episodes of proteinuria.  We estimated rates of incident proteinuria in subgroups of patients defined by time-invariant and time-varying predictors. 

Results: Among 895 patients included in the analysis, 840(94%) were  female, and 518 (58%) were Caucasian, 304 (34%) African-American, with mean age of 42 at the start of follow-up. We observed 58 incident cases of proteinura over a span of 4669 person-years of cohort follow-up. The overall rate of incident proteinuria was 12.4 per 1000 person-years.  The Table shows the association between select predictors and the rate incident proteinuria.  The rate was significantly lower among those of older age, and significantly higher among those who were not Caucasian.  Among those with a history of low C3, the rate was 8 times higher, and highest among those with a recent measure of low C3.  The rate among those prescribed hydroxychloroquine was similar to those not prescribed hydroxychloroquine.  Among those taking medicine for hypertension, the rate among those prescribed ACE inhibitor or ARB was similar to the rate among those prescribed other treatments.   Table :  Rates of incident proteinuria by patient characteristics.

Subgroup

Observed Number of new cases of proteinuria

Person-years of follow-up

Rate of events per 1000 py’s

Rate Ratios

P-value

Everyone

58

4669

12.4

 

 

Age   18-39   40-49   50-59   60+

 

39

11

5

2

 

1515

1171

1183

780

 

25.7

9.4

4.2

2.5

 

1.0 (Ref)

0.4 (0.2, 0.7)

0.2 (0.1, 0.4)

0.1 (0.0, 0.4)

 

 

0.0031

0.0001

0.0013

Sex   Female   Male

 

54

4

 

4376

293

 

12.3

13.7

 

1.0 (Ref)

1.1 (0.4, 3.1)

 

 

0.84

Ethnicity   Caucasian American   African American   Other

 

20

30

8

 

2803

1548

319

 

7.1

19.4

25.1

 

1.0 (Ref)

2.7 (1.5, ,4.8)

3.5 (1.6, 8.0)

 

 

0.0005

0.0026

Ever Low  C3     No     Yes

 

7

51

 

2463

2205

 

2.8

23.1

 

1.0 (Ref)

8.2 (3.7, 18.0)

 

 

<0.0001

Recent Low  C3     No     Yes

 

26

32

 

3893

559

 

6.7

57.2

 

1.0 (Ref)

8.6 (5.1, 14.4)

 

 

<0.0001

Ever anti-dsDNA     No     Yes

 

9

49

 

1928

2740

 

4.7

17.9

 

1.0 (Ref)

3.8 (1.9,7.8)

 

 

0.0002

Recent anti-dsDNA     No     Yes

 

17

41

 

3636

810

 

4.7

50.6

 

1.0 (Ref)

10.9 (6.2, 19.1)

 

 

<0.0001

Currently on Plaquenil?     No     Yes

 

11

46

 

699

3783

 

15.7

12.2

 

1.0 (Ref)

0.8(0.4, 1.5)

 

 

0.44

Currently on ACE/ARB1     No     Yes

 

10

24

 

628

1592

 

15.9

15.1

 

1.0 (Ref)

0.9 (0.5, 2.0)

 

 

0.89

 

Conclusion: Older SLE patients who have not previously had renal involvement are at low risk for developing proteinuria.  There was not strong evidence that hydroxychloroquine or ACE inhibitor’s reduced the risk of proteinuria. The highest rates of incident proteinuria were among those with recent low complement.  These results suggest that those with declines in complement should be monitored closely for renal disease.  


Disclosure: L. S. Magder, None; A. Duarte-Garcia, None; E. Barr, None; M. Petri, None.

To cite this abstract in AMA style:

Magder LS, Duarte-Garcia A, Barr E, Petri M. Predictors of Incident Episodes of Proteinuria Among Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/predictors-of-incident-episodes-of-proteinuria-among-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-incident-episodes-of-proteinuria-among-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology